UB Paderborn / Katalog / Suche / in CDI

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

Advances in therapy, 2017-01, Vol.33 (12), p.2160-2172

2017

Link zum Volltext

Verfügbarkeit prüfen

Biosimilars of anti‐vascular endothelial growth factors for ophthalmic disease – Clinical trial status 2022

Acta ophthalmologica (Oxford, England), 2022-12, Vol.100 (S275), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Biosimilars of anti‐vascular endothelial growth factors for ophthalmic disease – Clinical trial status 2021

Acta ophthalmologica (Oxford, England), 2022-01, Vol.100 (S267), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

The safety of switching between therapeutic proteins

Expert opinion on biological therapy, 2012-11, Vol.12 (11), p.1473-1485

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical experience with Zarzio® in Europe: what have we learned?

Supportive care in cancer, 2013-10, Vol.21 (10), p.2925-2932

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-15-19: Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-15-19

2015

Link zum Volltext

Verfügbarkeit prüfen

Two Innovative Pharmaceutical Forms of Leuprorelin: Results from 818 Patients with Advanced Prostate Cancer

Advances in therapy, 2013-03, Vol.30 (3), p.271-285

2013

Link zum Volltext

Verfügbarkeit prüfen

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

Critical reviews in oncology/hematology, 2011-03, Vol.77 (3), p.184-197

2011

Link zum Volltext

Verfügbarkeit prüfen

018–Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study In An Integrated Healthcare System

Journal of pediatric nursing, 2015-03, Vol.30 (2), p.432-432

2015

Link zum Volltext

Verfügbarkeit prüfen

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

European journal of cancer (1990), 2009-01, Vol.45 (1), p.8-11

2009

Link zum Volltext

Verfügbarkeit prüfen

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments

Critical reviews in oncology/hematology, 2011-03, Vol.77 (3), p.198-200

2011

Link zum Volltext

Verfügbarkeit prüfen

Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow-on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic Analysis

Journal of clinical pharmacology, 2010-11, Vol.50 (11), p.1339-1348

2010

Link zum Volltext

Verfügbarkeit prüfen

A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study

Internal and emergency medicine, 2013-08, Vol.8 (5), p.389-399

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Blood, 2008-11, Vol.112 (11), p.4706-4706

2008

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Blood, 2008-11, Vol.112 (11), p.4715-4715

2008

Link zum Volltext

Verfügbarkeit prüfen

Management of Anemia in Multiple Myeloma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Blood, 2008-11, Vol.112 (11), p.4716-4716

2008

Link zum Volltext

Verfügbarkeit prüfen

Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Blood, 2008-11, Vol.112 (11), p.4672-4672

2008

Link zum Volltext

Verfügbarkeit prüfen

Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Biologics in therapy, 2014-12, Vol.4 (1-2), p.81-81

2014

Link zum Volltext

Verfügbarkeit prüfen

Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Biologics in therapy, 2014-12, Vol.4 (1-2), p.27-39

2014

Link zum Volltext

Verfügbarkeit prüfen

Erratum to: Switching to Omnitrope^sup ^ from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Biologics in therapy, 2014-11, Vol.4 (1-2), p.81

2014

Link zum Volltext

Verfügbarkeit prüfen

Switching to Omnitrope^sup ^ from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Biologics in therapy, 2014-08, Vol.4 (1-2), p.27

2014

Link zum Volltext

Verfügbarkeit prüfen

Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care

Supportive care in cancer, 2007-11, Vol.15 (11), p.1325-1329

2007

Link zum Volltext

Verfügbarkeit prüfen

Promoting evidence-based management of anemia in cancer patients: Background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines

Critical reviews in oncology/hematology, 2008-01, Vol.65 (1), p.32-42

2008

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of leptin action and leptin resistance

Annual review of physiology, 2008-01, Vol.70 (1), p.537-556

2008

Link zum Volltext

Verfügbarkeit prüfen

FGF21 is an endocrine signal of protein restriction

The Journal of clinical investigation, 2014-09, Vol.124 (9), p.3913-3922

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

Biosimilars of anti‐vascular endothelial growth factors for ophthalmic disease – Clinical trial status 2022

Biosimilars of anti‐vascular endothelial growth factors for ophthalmic disease – Clinical trial status 2021

The safety of switching between therapeutic proteins

Clinical experience with Zarzio® in Europe: what have we learned?

Abstract P5-15-19: Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort

Two Innovative Pharmaceutical Forms of Leuprorelin: Results from 818 Patients with Advanced Prostate Cancer

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

018–Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study In An Integrated Healthcare System

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments

Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow-on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic Analysis

A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study

Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Management of Anemia in Multiple Myeloma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study

Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Erratum to: Switching to Omnitrope^sup ^ from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Switching to Omnitrope^sup ^ from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care

Promoting evidence-based management of anemia in cancer patients: Background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines

Mechanisms of leptin action and leptin resistance

FGF21 is an endocrine signal of protein restriction

Suchergebnisse filtern